The head and neck cancers (HNC) are a group of cancers that begin in the squamous cells that line the mucosal surfaces of the head and neck. Therefore, they are commonly known as squamous cell carcinoma of the head and neck. Squamous cell carcinoma of the maxillary sinus (MC) is a rare type of HNC, and it is a very aggressive tumour. This cancer is typically diagnosed at a very advanced stage and most patients have a poor survival rate and prognosis. This study is based on the synthesis and applications of gold nanoparticles (AuNPs) conjugated with hesperidin (Hsp) as a targeted drug delivery system. AuNPs are ideal for loading different drugs and delivering them to targets sites due to their stability, small size, substantial surface area, non-cytotoxic and inert nature. Hsp is a naturally occurring substance with anti-inflammatory and antioxidant capabilities. The main aim of this research was to develop a highly efficient and safer method to deliver Hsp to the target sites. The Hsp with poor solubility and bioavailability render it only slightly absorbed, requiring a delivery system to reach its therapeutic target. This study focused on the effects of 15μg/ml Hsp loaded on gold nanoparticles (Hsp-AuNPs) on 20 healthy individuals’ lymphocytes as compared to 20 HNC patients’ lymphocytes using the alkaline Comet assay. While enzyme-based Comet repair was performed on 5 healthy individuals’ lymphocytes as compared to 5 HNC patients’ lymphocytes. The Hsp-AuNPs reduced the DNA damage in HNC patients’ lymphocytes compared to the healthy lymphocytes (***p<0.001). Furthermore, the 15μg/ml of Hsp-AuNPs significantly reduced the oxidative stress caused by H2O2 and appeared to be effective in both groups using the Comet and Comet repair assay. Results from Comet and Comet repair assay were consistent. The human squamous cells of maxillary sinus (MC) were also treated with 5μg/ml of Hsp-AuNPs. The alkaline Comet assay results showed that Hsp-AuNPs induced DNA damage in MC cells (***p<0.001). Therefore, Hsp-AuNPs demonstrated the most substantial genotoxic effects and confirmed a possible anticancer agent. The Hsp was also used to treat lymphocytes from healthy individuals as compared to HNC patients’ lymphocytes they reduced the DNA damage, but they were less effective as compared to Hsp-AuNPs. Published data shows that using the AuNPs as a drug carrier has a more potent therapeutic effect against different diseases including cancer. Also, this study investigated the gene protective and genotoxic impact of bulk Hsp in Maxillary sinus carcinoma cells. The data obtained indicated that Hsp-AuNPs might possibly be effective for the treatment of MC and demonstrated the ability of Hsp-AuNPs to increase the DNA damage more than the bulk form of Hsp (***p<0.001). The outcomes of this study are consistent with the viewpoint that the Hsp-AuNPs might have a substantial role in cancer treatment, including MC. The concentration of 5μg/ml Hsp-AuNPs was used to treat the MC cells in Western blotting, and real-time polymerase chain reaction (qPCR) was based on a preliminary test for the optimal dose. The data obtained indicated that Hsp-AuNPs might potentially be effective for the treatment of HNC and showed the ability of Hsp-AuNPs to reduce DNA damage more than the bulk form of Hsp. Hsp-AuNPs has also shown anti-cancer potential in the MC cells by up-regulating the expression of p53, p21, PPAR gamma, and Caspase 3, at mRNA and protein levels by up-regulating the p53, PPAR gamma, Caspase 3, and p21 to mediate apoptosis and DNA repair in MC cells. The findings of this study are consistent with the view that the Hsp-AuNPs could have a significant role in cancer treatment, including HNC and MC.

Εισαγωγή: Ο καρκίνος του λάρυγγα, ιδιαιτέρως σε προχωρημένα στάδια, είναι μία καταστροφική νόσος η οποία χαρακτηρίζεται από αυξημένη διηθητικότητα και μεταστατικότητα. Η ανεύρεση ενός δείκτη πρώιμης διάγνωσης, παρακολούθησης και πρόγνωσης της νόσου θα ήταν ιδιαίτερα ευπρόσδεκτη. Συνεχώς αυξανόμενα δεδομένα στη βιβλιογραφία υποστηρίζουν την προγνωστική αξία των ζελατινασών και τον πιθανό ρόλο τους ως μοριακών δεικτών μεταξύ άλλων και στον καρκίνο του λάρυγγα. Σκοπός: Η διαπίστωση μεταβολών στα επίπεδα ορού των ζελατινασών Α και Β σε ασθενείς με καρκίνο του λάρυγγα μετά από εφαρμογή θεραπείας, καθώς και η πιθανή συσχέτιση με διάφορες κλινικοπαθολογικές παραμέτρους πριν και μετά τη θεραπευτική παρέμβαση. Υλικό και μέθοδος: Σαράντα εννέα ασθενείς και 8 υγιείς μάρτυρες συμπεριλήφθηκαν στη μελέτη. Ελήφθησαν προεγχειρητικά και μετεγχειρητικά δείγματα ορού τα οποία στη συνέχεια υποβλήθηκαν σε ζυμογραφία ζελατίνης. Η παρουσία ζελατινασών επιβεβαιώθηκε με την τεχνική western blotting. Οι ζώνες λύσης ποσοτικοποιήθηκαν με τη χρήση Scion Image PC. Η ανάλυση των αποτελεσμάτων πραγματοποιήθηκε με το πρόγραμμα SPSS 17 (SPSS Inc, Chicago, IL, USA). Αποτελέσματα: Στα ζυμογραφήματα αποτυπώθηκαν μόνο οι λανθάνουσες μορφές των ενζύμων (προένζυμα). Τα προ της θεραπείας επίπεδα και των δύο ζελατινασών στον ορό του αίματος των ασθενών με καρκίνο του λάρυγγα ήταν σημαντικά υψηλότερα σε σχέση με αυτά των υγιών μαρτύρων. Ασθενείς με υπεργλωττιδικό καρκίνωμα και ενεργοί καπνιστές είχαν σημαντικά υψηλότερα επίπεδα proMMP-2 σε σχέση με ασθενείς που έπασχαν από γλωττιδικό καρκίνωμα και με πρώην καπνιστές αντίστοιχα. Ασθενείς με πρωτοδιαγνωσμένη νόσο και ασθενείς με λεμφαδενικές μεταστάσεις είχαν σημαντικά χαμηλότερα προ της θεραπείας επίπεδα proMMP-9 σε σχέση με ασθενείς που προσήλθαν με υποτροπή και με ασθενείς στους οποίους δεν διαπιστώθηκε επιχώρια νόσος αντίστοιχα. Κατά τη διάρκεια της συστηματικής παρακολούθησης τα επίπεδα της proMMP-2 στον ορό παρουσίασαν σημαντική αύξηση τις πρώτες 10 με 15 ημέρες μετά την εφαρμογή θεραπείας, για να μειωθούν σταδιακά εντός των επόμενων μηνών. Οι ενεργοί καπνιστές παρουσίασαν σημαντική μείωση των επιπέδων της proMMP-2 κατά την περίοδο παρακολούθησης, σε αντίθεση με τους πρώην καπνιστές οι οποίοι εμφάνισαν σημαντική αύξηση κατά το ίδιο χρονικό διάστημα. Οι ασθενείς σταδίου ΙΙ είχαν σημαντικά χαμηλότερα επίπεδα proMMP-2 σε σχέση με ασθενείς προχωρημένων σταδίων πέντε με οκτώ μήνες μετά τη θεραπεία, όπως και οι ασθενείς οι οποίοι υποβλήθηκαν σε συντηρητική αντιμετώπιση σε σχέση με τους χειρουργημένους ασθενείς. Τα επίπεδα της proMMP-9 στον ορό επίσης παρουσίασαν σημαντική πτώση μετά την εφαρμογή θεραπείας. Διαφορές στο ρυθμό μείωσης των επιπέδων της proMMP-9 παρατηρήθηκαν μεταξύ των διαφόρων ομάδων ως προς το στάδιο, τη διαφοροποίηση, την εντόπιση, τον τύπο της νόσου (πρωτοδιαγνωσμένη ή υποτροπή), τις λεμφαδενικές μεταστάσεις, τον τρόπο αντιμετώπισης και την κατανάλωση αλκοόλ. Ωστόσο αυτή η διαφορά δεν διατηρήθηκε πέντε με οκτώ μήνες μετά την εφαρμογή θεραπείας, με εξαίρεση την ομάδα των χειρουργημένων ασθενών, οι οποίοι διατήρησαν σημαντικά υψηλότερα επίπεδα ενζύμου στον ορό. Αύξηση των ζελατινασών παρατηρήθηκε στον ορό ασθενών που εκδήλωσαν υποτροπή μετά από αντιμετώπιση πρωτοδιαγνωσμένης νόσου σε σχέση με αυτούς που δεν υποτροπίασαν. Ωστόσο εξαιτίας του μικρού δείγματος δεν είναι δυνατόν να εξαχθούν ασφαλή συμπεράσματα. Συμπεράσματα: Αν και δεν υφίστανται φυσιολογικές τιμές, το πρότυπο μεταβολής των επιπέδων της proMMP-9 στον ορό μετά από θεραπεία καταδεικνύει πιθανές ιδιότητες μοριακού δείκτη. Ωστόσο υπάρχουν ενδείξεις ότι και οι δύο ζελατινάσες θα μπορούσαν να χρησιμοποιηθούν για την εξατομικευμένη παρακολούθηση ασθενών με καρκίνο του λάρυγγα. Περαιτέρω έρευνα απαιτείται για την αποσαφήνιση του ζητήματος. / Introduction: Laryngeal cancer, especially in the advanced stages, is a highly devastating disease, characterized by increased invasiveness and high rates of metastasis. The identification of reliable tumour marker for prompt diagnosis, surveillance and prognosis would be highly desirable. There is a growing body of evidence with regard to the prognostic value of gelatinases and their possible role as tumour markers. Aim: To identify the pattern of alteration of serum gelatinases A and B in patients with laryngeal cancer following treatment, and a possible correlation with various clinicopathological parameters prior to and past treatment. Materials and methods: Forty nine patients and 8 healthy controls were included in the study. Pre-treatment and post-treatment serum samples were collected and processed by gelatin zymography. The presence of gelatinases was verified by western blotting. The zymograms were scanned by a digital scanner and the lysis bands were quantified by Scion Image PC. Analysis of the quantitative results was performed by using SPSS 17 (SPSS Inc, Chicago, IL, USA). Results: Only the latent forms of MMP-2 and -9 (proforms) were identified. Both gelatinases were increased in the serum of laryngeal cancer patients compared to healthy individuals. Patients with supraglottic tumours and active smokers had significantly higher pre-treatment levels of proMMP-2 than patients with glottic tumours and ex-smokers, respectively. Patients with primary disease and patients with lymph node involvement showed lower proMMP-9 pre-treatment levels than patients with recurrence and patients without neck disease, respectively. During the follow-up period the proMMP-2 serum levels increased significantly in the first ten to fifteen days after treatment, gradually decreasing over the following months. Smokers showed a very high decrease rate of proMMP-2 levels during the follow-up period, whereas in ex-smokers proMMP-2 levels significantly increased. Stage II patients showed significantly lower levels of circulating enzyme compared to patients with more advanced disease five to eight months past treatment. Similarly, conservative management was associated with lower levels of serum proMMP-2 compared to surgical management five to eight months following treatment. The proMMP-9 serum levels also showed a gradual decrease after treatment, which was statistically significant. Significant alterations in the rate of decrease developed among groups with regard to stage, grade, location, type of disease (primary or recurrence), regional disease, treatment modality and alcohol consumption. Nevertheless those differences were not maintained five to eight months past treatment, with the exception of patients who underwent surgery and who maintained higher levels of proMMP-9. An increase to the levels of both gelatinases were observed in patients with recurrent disease after having been treated for a primary compared to patients who did not develop a recurrence. However, the small sample of patients with recurrent disease during the follow-up period does not allow extrapolating sound conclusions. Conclusions: Although as yet normal values have not been established in the literature, the post-treatment alteration pattern of proMMP-9 serum levels indicates that this enzyme might play a role as a tumour marker. Nevertheless this study provides evidence that both gelatinases might be useful for surveillance on strictly individual basis in laryngeal cancer patients. Further research is necessary to clarify the contribution of both gelatinases to the disease progress and determine their role as prognostic factors and tumour markers.

Introduction: Les mutations du gène RAS sont présentes dans plusieurs types de cancers et ont une influence sur la réponse à la chimiothérapie. Excision repair cross- complementation group 1 (ERCC1) est un gène impliqué dans la réparation de l’acide désoxyribonucléique (ADN), et son polymorphisme au codon 118 est également associé à la réponse au traitement. Le peu d’études pronostiques portant sur ces deux gènes dans les cancers oto-rhino-laryngologiques (ORL) ne permet de tirer des conclusions claires. Objectifs: Déterminer l’influence des mutations de K-RAS codons 12 et 13 et du polymorphisme de ERCC1 codon 118 dans le traitement des cancers épidermoïdes avancés tête et cou traités par chimioradiothérapie concomitante à base de sels de platine. Méthode: Extraction de l’ADN provenant de spécimens de biopsie de patients traités par chimioradiothérapie concomitante pour des cancers avancés tête et cou, et ayant un suivi prospectif d’au moins deux ans. Identification des mutations de K-RAS codons 12 et 13 et du polymorphisme de ERCC1 au codon 118 dans les spécimens et corrélation de ces marqueurs avec la réponse au traitement. Résultats: Les mutations de K-RAS codon 12 sont associées à un moins bon contrôle loco-régional par rapport aux tumeurs ne démontrant pas la mutation (32% vs 83% p=0.03), sans affecter pour autant la survie globale. Aucune mutation de K-RAS codon 13 n’a été identifiée. Les différents polymorphismes de ERCC1 n’ont pas eu d’impact sur la réponse au traitement. Conclusion: Les mutations de K-RAS codons 12 et 13 et le polymorphisme de ERCC1 au codon 118 ne semblent pas mettre en évidence les patients qui bénéficieraient d’une autre modalité thérapeutique. / Background: RAS gene mutations have been shown to occur in certain malignancies and have an impact treatment response and overall prognosis. Excision repair cross- complementation group 1 (ERCC1) is a gene implicated in deoxyribonucleic acid (DNA) repair, whose polymorphism at codon 118 has been linked to treatment response. Studies of these two genes in head and neck oncology literature have shown inconsistent results. Objectives: Determine the influence of K-RAS mutations (codons 12 and 13) and the polymorphism of ERCC1 codon 118 in patients with locally advanced head and neck cancer treated with concomitant platinum-based chemoradiation therapy. Methods: DNA extraction from paraffin-embedded biopsy specimens of patients with advanced head and neck squamous cell carcinoma treated with concomitant chemoradiation and followed prospectively for at least two years. Identification of K- RAS mutations (codons 12 and 13) and ERCC1 codon 118 polymorphism in the extracted DNA. Correlation of these markers with treatment response. Results: K-RAS codon 12 mutations were associated with a worse locoregional control than tumors without any mutations (32% vs 83% p=0.03); however, mutational status did not influence overall survival. No K-RAS codon 13 mutation was identified in our specimens. The different ERCC1 polymorphisms did not have an impact on treatment response. Conclusion: K-RAS mutational status (codon 12 and 13) and ERCC1 codon 118 polymorphism does not seem to discriminate between patients for whom another treatment option should be sought in patients with locally advanced head and neck squamous cell carcinoma.

Le virus du papillome humain (HPV) est l’infection sexuellement transmise la plus fréquente au monde. Plusieurs études ont établi son implication dans l’étiologie de pratiquement tous les cancers du col de l’utérus, une maladie qui constitue un problème de santé majeur dans les pays pauvres. Le HPV est également responsable de 90% des cancers de l’anus, 40-50% des cancers du pénis, de la vulve et du vagin, et 30% des cancers de la tête et du cou. L’objectif général de cette thèse est de combler les lacunes relatives aux connaissances sur la distribution génotypique du HPV dans les lésions néoplasiques cervicales utérines et de la tête et du cou, plus particulièrement en Afrique. Les objectifs spécifiques sont les suivants: 1) analyser la distribution génotypique du HPV dans les cancers du col de l’utérus et faire une analyse comparative de cette distribution dans cinq pays africains en fonction de la prévalence du VIH; 2) évaluer la présence du HPV dans les cancers de la tête et du cou au Sénégal; 3) faire une revue de la littérature et une méta-analyse sur la distribution du HPV dans les cancers de la tête et du cou dans toutes les régions du monde. Pour le premier et le second objectifs, qui découlent d’un large projet international coordonné par l’Institut Catalan d’Oncologie pour l’Organisation Mondiale de la Santé (OMS), une étude transversale multicentrique a été menée au Mali et au Sénégal pour collecter des blocs de paraffine de patientes diagnostiquées entre 2001 et 2010 du cancer invasif du col et des cancers de la tête et du cou. Pour le troisième objectif, une revue exhaustive de la littérature a permis d’identifier tous les articles qui ont été publiés sur les cancers de la tête et du cou dans tous les pays du monde et d’effectuer une méta-analyse sur la prévalence de l’ADN du HPV selon le site du cancer et la région géographique. Notre analyse montre que les principaux types de HPV ciblés dans les vaccins prophylactiques (HPV16/18) représentent la majorité des types de HPV détectés dans le cancer invasif du col de l’utérus en Afrique subsaharienne. Par contre, le HPV45 vient au second rang dans certains pays d’Afrique, dont le Mali et le Sénégal. Nos données suggèrent également que le VIH aurait un rôle dans la contribution relative du HPV18 et HPV45 dans le développement du cancer du col de l’utérus. Au Sénégal, notre étude montre que la prévalence du HPV dans les cancers de la tête et du cou est très faible et ne semble pas jouer un rôle important dans l’oncogenèse. Finalement, la méta-analyse a mesuré la prévalence des HPV dans les cancers de la cavité orale, de l’oropharynx, du larynx et de l’hypopharynx, et confirme l’importante contribution relative du HPV16 dans ces cancers. Globalement, cette thèse permet de mieux comprendre l’impact potentiel des vaccins prophylactiques sur l’incidence des cancers associés au HPV. / Human papillomavirus (HPV) infection is the most common sexually transmitted infection worldwide. Several studies have shown its involvement in the etiology of virtually all cancers of the cervix, which is a major health problem in poor countries. HPV is also responsible for 90% of anal cancers, 40-50% of penile, vulvar and vaginal cancers, and 30% of head and neck cancers. The overall objective of this thesis is to fill the gaps in knowledge on the genotype distribution of HPV in anogenital and head and neck neoplasia, especially in sub-Saharan Africa. The specific objectives are to: 1) analyze HPV genotype distribution in cervical cancer and compare this distribution in five African countries according to HIV prevalence; 2) evaluate the presence of HPV in cancers of the head and neck in Senegal; 3) review the literature on the distribution of HPV in cancers of the head and neck in all regions of the world and perform a meta-analysis. For the first and second objectives, which were derived from a larger international project coordinated by the Catalan Institute of Oncology for the World Health Organization (WHO), a cross-sectional multicentric study was conducted to collect paraffin-embedded blocks of invasive cervical cancer and head and neck cancer diagnosed between 2001 and 2010 in Mali and Senegal. For the third objective, a comprehensive search of the literature was conducted to identify all articles published to date on head and neck cancer. A meta-analysis was performed to estimate the prevalence of HPV DNA according to cancer site and geographical region. Our analysis shows that the main HPV types targeted in the prophylactic vaccines (HPV16/18) accounted for the majority of the HPV types found in invasive cervical cancer in sub-Saharan Africa. Our data also suggests that HIV may play a role in the contribution of HPV18 and HPV45 to the development of cervical cancer. However, HPV45 ranks second in many African countries, notably in Mali and Senegal. In Senegal, our study shows that HPV DNA prevalence in head and neck cancer is very low and is not importantly involved in the oncogenesis. Finally, the meta-analysis measured the prevalence of HPV in cancers of the oral cavity, oropharynx, larynx and hypopharynx, and confirmed the significant relative contribution of HPV16 in these cancers. Overall, this thesis contributes to a better understanding of the potential impact of HPV prophylactic vaccines on the incidence of HPV-associated cancers.

Le suppresseur de tumeur DOK1 (downstream of tyrosine kinases1) est une protéine régulatrice de voies de signalisation impliquées dans des processus cellulaires tel que la prolifération, la migration et l'apoptose. Le rôle suppresseur de tumeur de DOK1 a été démontré dans des modèles animaux. Les souris knock-out pour DOK1 présentent une forte susceptibilité de développer des leucémies, des tumeurs malignes hématologiques, des adénocarcinomes pulmonaires, ainsi que des sarcomes histiocytaires agressifs. En outre, nous avons rapporté précédemment que le gène DOK1 peut être muté et son expression réprimée dans différentes tumeurs malignes humaines, telles que les lignées cellulaires de lymphome de Burkitt (BL) et la leucémie lymphoïde chronique (LLC). Cependant, les mécanismes de dérégulation de DOK1 restent inconnus, notamment dans les processus de carcinogenèse induite ou non par des oncovirus. Dans ce projet de thèse, nous avons d'abord caractérisé le promoteur de DOK1 et le rôle du facteur de transcription E2F1 comme le principal régulateur de l'expression de DOK1. Nous avons démontré pour la première fois la contribution de DOK1 dans la réponse cellulaire au stress par son rôle suppresseur de prolifération cellulaire et promoteur d'apoptose. Nous avons trouvé que l'expression du gène DOK1 est réprimée dans une variété de cancers humains, y compris le cancer de la tête et du cou, les lymphomes de Burkitt et les cancers du poumon. Cette répression est due à l'hyperméthylation aberrante de DOK1. Nous avons donc étudié les événements épigénétiques, qui sont souvent altérés dans les cancers, et leurs implications dans la répression de DOK1 dans les lignes cellulaire cancéreuses de la tête et du cou. Nous nous sommes par la suite intéressés aux mécanismes de dérégulation de DOK1 par le virus d'Epstein Barr dans le cadre de sa propriété oncogénique dans les lymphocytes B humains ainsi que dans les lignes cancéreuses du lymphome de Burkitt. Nos résultats apportent de nouvelles informations sur les mécanismes de régulation de l'expression de DOK1 dans la carcinogenèse induite ou non par des oncovirus, ce qui pourrait le définir comme un biomarqueur potentiel de cancer et comme une cible intéressante pour des thérapies épigénétiques / The newly identified tumor suppressor DOK1 (downstream of tyrosine kinases1) inhibits cell proliferation, negatively regulates MAP kinase activity, opposes leukemogenesis, and promotes cell spreading, motility, and apoptosis. DOK1 also plays a role in the regulation of immune cell activation, including B cells. The tumor suppressor role of DOK1 was demonstrated in animal models. DOK1 knockout mice show a high susceptibility to develop leukemia, hematological malignancies as well as lung adenocarcinomas and aggressive histiocytic sarcoma. In addition, we previously reported that the DOK1 gene can be mutated and its expression is down-regulated in human malignancies such as Burkitt’s lymphoma cell lines (BL) and chronic lymphocytic leukemia (CLL). However, very little is known about the mechanisms underlying DOK1 gene regulation and silencing in viral- and non viral-related tumorigenesis. In the present project, we first characterized the DOK1 promoter. We have shown the role of E2F1 transcription factor as the major regulator of DOK1 expression and how DOK1 plays a role in DNA stress response though opposing cell proliferation and promoting apoptosis. We demonstrated that DOK1 gene expression is repressed in a variety of human cancers, including head and neck, Burkitt’s lymphoma and lung cancers, as a result of aberrant hypermethylation. We investigated the link between the epigenetic events and DOK1 silencing in non viral head and neck cancer cell lines, and by Epstein Barr virus in relation to its oncogenic activity in human B cells and neoplasia such as Burkitt’s lymphoma. These data provide novel insights into the regulation of DOK1 in viral and non viral-related carcinogenesis, and could define it as a potential cancer biomarker and an attractive target for epigeneticbased therapy

Made available in DSpace on 2016-01-26T12:51:27Z (GMT). No. of bitstreams: 1 mauriciojosecabralruback_dissert.pdf: 5807633 bytes, checksum: a0c4cdc248961c9493b92c90b20f7705 (MD5) Previous issue date: 2010-12-13 / The head and neck surgery service assist patients with malignant tumors of upper aero digestive tract, skin and thyroid. Head and neck cancer is currently the fifth most worldwide common cancer and despite advances in conventional therapies, including surgery, radiotherapy and chemotherapy, the survival rate has not changed in the last three decades. In Brazil, estimatives shows 14.120 new cases of oral cavity cancer in 2010, with 3.790 women and 10.330 men. Objectives: To evaluate the clinical and epidemiological parameters in patients with cancer assisted by head and neck surgery service at the University Hospital of northwest region of São Paulo. Casuistic and Methods: Were retrospectively evaluated medical records of 1.351 patients of head and neck surgery service from january 2000 to may 2010. The variables analyzed were: age, gender, skin color, tobacco and alcohol consumption, primary site, staging and histologic type of tumor, treatment, number of deaths and occupational activity of patients assisted by head and neck surgery service. Results: The disease was more frequent in men (79.70%), smokers (75.15%) and etilist (58.25%). The most frequents sites were oral cavity (29.65%) and larynx (24.12%). The most common histological type was squamous cell carcinoma (84.92%) and 29.04% of individuals had as treatment surgical and 14,19 % radiotherapy Conclusions: This cancer type occurs more common in men smokers and etilists. The primary sites more incident for the patients service are oral cavity and larynx. The high rate of patients with stages III and IV indicates a late diagnosis by the treatment centers, which reflects the need for prevention education campaigns for early diagnosis of the disease. / O serviço de cirurgia de cabeça e pescoço atende pacientes com tumores malignos do trato aéreo digestivo superior, de pele e tireóide. O tumor maligno de cabeça e pescoço é atualmente a quinta neoplasia mais comum de todo o mundo e apesar dos avanços em terapias convencionais, incluindo cirurgia, radioterapia e quimioterapia, a taxa de sobrevida não mudou nas ultimas três décadas. No Brasil, as estimativas revelam 14.120 casos novos de câncer de cavidade oral para 2010, sendo que 3.790 em mulheres e 10.330 em homens. Objetivos: Avaliar os parâmetros clínicos e epidemiológicos em pacientes com câncer atendidos no serviço de cirurgia de cabeça e pescoço em um Hospital Universitário da região noroeste do estado de São Paulo. Casuística e Método: Foram avaliados retrospectivamente prontuários médicos de 1.351 pacientes do serviço de cirurgia de cabeça e pescoço no período de janeiro de 2000 a maio de 2010. As variáveis analisadas foram: idade, gênero, cor da pele, hábitos tabagista e etilista, sítio primário, estadiamento, tipo histológico do tumor, tratamento, número de óbitos e atividade ocupacional dos pacientes atendidos no serviço de cirurgia de cabeça e pescoço. Resultados: Esta doença foi mais frequente em homens (79,70%), tabagistas (75,15%) e elitistas (58,25%). Os sítios primários mais freqüentes foram cavidade oral (29,65%) e laringe (24,12%). O carcinoma espinocelular foi o tipo histológico (84,92%) mais comum e 29,04% dos indivíduos tiveram a cirurgia como tratamento e 14,19% radioterapia. Conclusões: Este tipo de neoplasia é mais freqüente em homens tabagistas e etilistas. Os sítios primários mais acometidos nos pacientes do serviço são cavidade oral e laringe. A alta taxa de pacientes com estadios III e IV indica uma procura tardia dos centros de tratamento, o que reflete a necessidade de campanhas de prevenção educativas para o diagnóstico precoce da doença.

Made available in DSpace on 2016-01-26T12:51:35Z (GMT). No. of bitstreams: 1 analiviasilvagalbiatti_dissert.pdf: 5592872 bytes, checksum: fdca0cebd9505cc0ed6bc31954c386de (MD5) Previous issue date: 2010-09-24 / O carcinoma de cabeça e pescoço pode ser decorrente de alterações na metilação do DNA associadas ao metabolismo anormal do folato. Concentrações reduzidas desse nutriente podem diminuir a capacidade de reparo do DNA, resultando em alterações celulares malignas que modulam a função e expressão dos genes. Polimorfismos em genes que participam da via do folato têm sido investigados como fatores de risco para susceptibilidade ao carcinoma de cabeça e pescoço, entre eles, polimorfismos nos genes MTR, RFC1, CBS e MTHFR. Objetivos: Estabelecer a freqüência dos polimorfismos nos genes MTR (A2756G), RFC1(A80G), CBS (844 ins 68) e MTHFR (C677T e A1298C) em pacientes com carcinoma de cabeça e pescoço comparando-a com aquela observada em indivíduos sem história de neoplasia; avaliar a associação dos polimorfismos com os hábitos tabagista e etilista, gênero e idade e verificar associação entre os polimorfismos e parâmetros clínico-histopatológicos. Casuística e Método: Foram incluídos no estudo 854 indivíduos (322 pacientes com carcinoma de cabeça e pescoço e 531 indivíduos controles). Para análise molecular, o DNA genômico foi extraído a partir de leucócitos de sangue periférico e as técnicas de reação em cadeia da polimerase e digestão enzimática foram utilizadas para genotipagem dos indivíduos estudados. Os dados sócio-demográficos foram obtidos a partir do prontuário médico do paciente e entrevista realizada aos indivíduos controle. Para análise estatística foi utilizado os testes de qui-quadrado e regressão logística múltipla. Resultados: Em relação ao polimorfismo MTR A2756G, os resultados mostraram que os hábitos tabagista e etilista, idade acima de 42 anos, gênero masculino, genótipo 2756AG e alelo polimórfico 2756G podem aumentar o risco de carcinoma de cabeça e pescoço (p<0,05). Houve alta freqüência do alelo MTR 2756G em pacientes do gênero masculino (p<0,05). A avaliação do polimorfismo RFC1 A80G mostrou que gênero masculino, hábito tabagista e genótipos RFC1 80AG ou GG foram associados com risco aumentado da doença. O polimorfismo CBS 844ins68 não foi associado com o risco de carcinoma de cabeça e pescoço e houve alta freqüência dessa variante em pacientes que possuíam como sítio primário a cavidade oral. A análise para os polimorfismos no gene MTHFR (C677T e A1298C) mostrou que idade avançada, gênero masculino, hábitos tabagista e etilista, genótipos MTHFR 1298AC ou CC e genótipos combinados MTHFR 677CT/1298AC, 677TT/1298AC, 677CT/1298CC e 677TT/1298CC foram associados com aumento de risco para o carcinoma de cabeça e pescoço (p<0,05). Houve freqüência maior do que esperada do haplótipo MTHFR 677C-1298A e freqüência menor que esperada dos haplótipos 677T-1298C e 677C- 1298C em ambos grupos (p<0,05). O polimorfismo MTHFR A1298C foi mais freqüente em pacientes que possuíam como sítio primário a cavidade oral. Conclusões: O carcinoma de cabeça e pescoço é mais frequente em homens, com idade acima de 42 anos, fumantes e etilistas. Os polimorfismos MTR A2756G, RFC1 A80G, MTHFR A1298C e os polimorfismos combinados A1298C e C677T do gene MTHFR podem modular o risco para o carcinoma de cabeça e pescoço. / O carcinoma de cabeça e pescoço pode ser decorrente de alterações na metilação do DNA associadas ao metabolismo anormal do folato. Concentrações reduzidas desse nutriente podem diminuir a capacidade de reparo do DNA, resultando em alterações celulares malignas que modulam a função e expressão dos genes. Polimorfismos em genes que participam da via do folato têm sido investigados como fatores de risco para susceptibilidade ao carcinoma de cabeça e pescoço, entre eles, polimorfismos nos genes MTR, RFC1, CBS e MTHFR. Objetivos: Estabelecer a freqüência dos polimorfismos nos genes MTR (A2756G), RFC1(A80G), CBS (844 ins 68) e MTHFR (C677T e A1298C) em pacientes com carcinoma de cabeça e pescoço comparando-a com aquela observada em indivíduos sem história de neoplasia; avaliar a associação dos polimorfismos com os hábitos tabagista e etilista, gênero e idade e verificar associação entre os polimorfismos e parâmetros clínico-histopatológicos. Casuística e Método: Foram incluídos no estudo 854 indivíduos (322 pacientes com carcinoma de cabeça e pescoço e 531 indivíduos controles). Para análise molecular, o DNA genômico foi extraído a partir de leucócitos de sangue periférico e as técnicas de reação em cadeia da polimerase e digestão enzimática foram utilizadas para genotipagem dos indivíduos estudados. Os dados sócio-demográficos foram obtidos a partir do prontuário médico do paciente e entrevista realizada aos indivíduos controle. Para análise estatística foi utilizado os testes de qui-quadrado e regressão logística múltipla. Resultados: Em relação ao polimorfismo MTR A2756G, os resultados mostraram que os hábitos tabagista e etilista, idade acima de 42 anos, gênero masculino, genótipo 2756AG e alelo polimórfico 2756G podem aumentar o risco de carcinoma de cabeça e pescoço (p<0,05). Houve alta freqüência do alelo MTR 2756G em pacientes do gênero masculino (p<0,05). A avaliação do polimorfismo RFC1 A80G mostrou que gênero masculino, hábito tabagista e genótipos RFC1 80AG ou GG foram associados com risco aumentado da doença. O polimorfismo CBS 844ins68 não foi associado com o risco de carcinoma de cabeça e pescoço e houve alta freqüência dessa variante em pacientes que possuíam como sítio primário a cavidade oral. A análise para os polimorfismos no gene MTHFR (C677T e A1298C) mostrou que idade avançada, gênero masculino, hábitos tabagista e etilista, genótipos MTHFR 1298AC ou CC e genótipos combinados MTHFR 677CT/1298AC, 677TT/1298AC, 677CT/1298CC e 677TT/1298CC foram associados com aumento de risco para o carcinoma de cabeça e pescoço (p<0,05). Houve freqüência maior do que esperada do haplótipo MTHFR 677C-1298A e freqüência menor que esperada dos haplótipos 677T-1298C e 677C- 1298C em ambos grupos (p<0,05). O polimorfismo MTHFR A1298C foi mais freqüente em pacientes que possuíam como sítio primário a cavidade oral. Conclusões: O carcinoma de cabeça e pescoço é mais frequente em homens, com idade acima de 42 anos, fumantes e etilistas. Os polimorfismos MTR A2756G, RFC1 A80G, MTHFR A1298C e os polimorfismos combinados A1298C e C677T do gene MTHFR podem modular o risco para o carcinoma de cabeça e pescoço.

O tratamento radioterápico é considerado como uma das modalidades terapêuticas padrão para os cânceres de cabeça e pescoço, cujo objetivo é controlar a evolução do tumor com o menor dano possível aos tecidos e órgãos normais adjacentes, porém, apesar de apresentar a vantagem de preservar a estrutura dos tecidos, pode acarretar reações adversas que se manifestam na cavidade oral, e também efeitos colaterais físicos generalizados, sendo a fadiga o mais comum. Objetivo: avaliar a efetividade da Prática Integrativa e Complementar - Relaxamento com Visualização Guiada, sobre a redução do sintoma de fadiga e melhora da Qualidade de Vida Relacionada à Saúde, durante o tratamento radioterápico. Método: estudo quantitativo, quase-experimental, de corte longitudinal e prospectivo, com a participação de 102 pacientes em início de tratamento radioterápico, com a alocação intencional em dois grupos, o de Intervenção (n=42) e o de Comparação (n=60). Apenas os participantes do Grupo Intervenção realizaram a prática de relaxamento com visualização guiada durante o tratamento radioterápico, porém, todos os participantes responderam aos questionários de avaliação. Foram utilizados os questionários de Qualidade de Vida Relacionada à Saúde (FACT H&N) e a Escala de Fadiga de Piper Revisada. A prática de relaxamento com visualização guiada foi aplicada pela pesquisadora do estudo, por meio de uma gravação de áudio contendo comandos verbais, os quais guiavam o paciente para a realização da prática. Para avaliar o efeito da intervenção entre os grupos intervenção e de controle, foi utilizada a técnica de regressão logística multinomial, estimando razões de chance (odds ratios) por pontos e respectivos erros-padrão (Ep). Resultados: na etapa descritiva dos dados sociodemográficos e clínicos, evidenciou-se a predominância do sexo masculino, faixa etária entre 41 e 60 anos, baixo nível de escolaridade, aposentados, católicos, em uso regular de álcool e tabaco, câncer de orofaringe, em estádio IV. Foram evidenciadas diferenças estatisticamente significativas entre os grupos em relação às variáveis procedência, estado civil e \"tipo de cirurgia\" e os valores-p foram, respectivamente, p=0,000, p= 0,002 e p=0,027. Na etapa analítica evidenciou-se que o relaxamento com visualização guiada mostrou-se efetivo em especial para os domínios global, comportamental e sensorial na segunda aplicação (T2), e afetivo e sensorial na terceira aplicação (T3), levando à redução do sintoma de fadiga, e quanto à Qualidade de Vida Relacionada à Saúde não houve diferença estatisticamente significativa entre os grupos. Conclusão: os resultados demonstraram que o relaxamento com visualização guiada não teve efeito na melhora da Qualidade de Vida Relacionada à Saúde durante o tratamento radioterápico nos pacientes com câncer de cabeça e pescoço, mas reduziu os níveis de fadiga. Trata-se de uma prática de baixo custo, a qual mostrou-se efetiva na redução do sintoma de fadiga, portanto, seu uso deve ser divulgado na prática dos cuidados aos pacientes oncológicos / Radiation therapy is considered to be one of the standard therapeutic modalities for head and neck cancers in order to control tumor evolution with the lowest possible damage to adjacent normal tissues and organs. Although it has the advantage of preserving the structure of tissues, it can lead to adverse reactions occurring in the oral cavity, as well as generalized physical side effects, being fatigue the most common of them. Objective: to evaluate the effectiveness of an Integrative and Complementary Practice - Relaxation with Guided Imagery, on the reduction of fatigue symptom and improvement of Health-Related Quality of Life, during the radiotherapy treatment. METHODS: A quantitative, quasi-experimental, longitudinal and prospective study was carried out with the participation of 102 patients at the beginning of radiotherapy, intentionally allocated in two groups: Intervention (n=42) and Comparison (n = 60). While only the participants of the Intervention Group performed the relaxation practice with guided imagery during the radiotherapy treatment, all the participants answered the evaluation questionnaires. The HealthRelated Quality of Life questionnaires (FACT-H&N) and the revised Piper Fatigue Scale were used. The practice of relaxation with guided imagery was applied by the researcher of the study, through an audio recording containing verbal commands, which guided the patient to perform the practice. To evaluate the effects of the intervention comparing the intervention and control groups, it was used multinomial logistic regression technique in order to estimate odds ratios by points and their respective standard errors (SE). Results: the descriptive stage found in the sociodemographic and clinical data, the prevalence of males, age between 41 and 60 years old, low level of schooling, retirees, Catholics, regular use of alcohol and tobacco, as well as oropharynx cancer in stage IV. There were statistically significant differences between the groups related to the variables place of residence, marital status and \"type of surgery\", while the p-values were respectively, p=0.000, p=0.002 and p = 0.027. In the analytical stage, it was observed that the relaxation with guided imagery was effective for the global, behavioral and sensorial domains in the second application (T2), as well as for the affective and sensorial domains in the third application (T3), leading to the reduction of the fatigue symptoms, while there was no statistically significant difference between the groups related to Health-Related Quality of Life. Conclusion: The results showed that while guided imagery relaxation had no effect on the improvement of the Health-Related Quality of Life during the radiotherapy treatment in patients with head and neck cancer, it still reduced fatigue levels. It is a low-cost practice, which has proved effective in reducing the fatigue symptoms, so its use must be disseminated in caring practices directed to cancer patients

Les vitamines B et les facteurs liés au métabolisme monocarboné (C1) aident à maintenir la synthèse de l'ADN, régulent l'expression des gènes, et peuvent affecter le risque de cancer. L'objectif général de cette thèse est d'étudier l'importance des biomarqueurs du C1 dans l'étiologie de trois cancers distincts qui diffèrent dans leur force d'association avec le tabagisme. Les articles inclus dans cette thèse ont été conduits au sein de deux études prospectives : l'étude prospective européenne sur la nutrition et le cancer (EPIC) et le consortium de cohortes du cancer du poumon (LC3). Dans l'article 1, nous avons étudié la relation entre les biomarqueurs du C1 et l'incidence ainsi que le pronostic du cancer de la sphère oto-rhino-laryngée (ORL) et de l'oesophage au sein de l'étude EPIC. Nous avons observé que les sujets ayant des concentrations élevées d'homocystéine avaient un risque accru de développer un cancer de la sphère ORL. Dans l'article 2, nous avons examiné la relation entre les biomarqueurs du C1 et l'incidence ainsi que le pronostic du carcinome à cellules rénales (CCR) au sein de l'étude EPIC. Nous avons constaté que les participants ayant des concentrations de vitamine B6 élevées avaient une diminution du risque de CCR avec un effet dose-réponse ainsi qu'une amélioration de la survie post-diagnostic. Dans l'article 3, nous avons étudié si les biomarqueurs du C1 sont associés au risque de cancer du poumon au sein de l'étude LC3. Dans l'ensemble, nous avons mis en exergue une faible association inverse, sans tendance claire, entre les concentrations de vitamine B6 et de folate et le risque du cancer du poumon. La principale conclusion de nos études est que les concentrations élevées de vitamine B6 sont associées à un risque plus faible de développer un CCR, et également à un meilleur pronostic chez les patients atteints de cette pathologie. Davantage d'études sont nécessaires afin d'évaluer si la vitamine B6 exerce une influence causale sur l'étiologie et la mortalité du CCR, ou si d'autres facteurs métaboliques sont impliqués / B-vitamins and factors related to one-carbon metabolism (OCM) pathway help to maintain DNA synthesis and regulate gene expression and may affect cancer risk. The overarching aim of this thesis is to investigate the importance of OCM biomarkers in the etiology of three distinct cancer sites that differed in their strength of association with smoking. Papers included in this thesis were conducted within two prospective studies, the European Prospective Investigation into nutrition and Cancer (EPIC) study and the Lung Cancer Cohort Consortium (LC3). In paper 1, we investigated if OCM biomarkers are associated with incidence and survival of cancer of the head and neck and esophagus in the EPIC study. We observed that subjects with higher concentrations of homocysteine had increased risk of developing head and neck cancer. In paper 2, we investigated if OCM biomarkers are associated with incidence and survival of renal cell carcinoma (RCC) in the EPIC study. We observed that study subjects with elevated vitamin B6 concentrations had lower risk of RCC in a dose-response fashion and improved survival following diagnosis. In paper 3, we investigated whether OCM factors are associated with lung cancer risk in the LC3 study. Overall, we observed a weak inverse association, with no clear trend, between concentrations of vitamin B6 and folate and risk of lung cancer. The most important conclusion is that elevated vitamin B6 concentrations are associated with lower risk of developing RCC, and also better prognosis among RCC cases. Further studies are warranted to evaluate if vitamin B6 exerts a causal influence on RCC etiology and mortality, or if other metabolic factors are involved

Chemo-radiation therapy is a principal modality for the treatment of head and neck cancers, and its efficacy depends on the interaction of tumor oxygen with free radicals. In this study, we adopted a novel hybrid diffuse optical instrument combining a commercial frequency-domain tissue oximeter (Imagent) and a custom-made diffuse correlation spectroscopy (DCS) flowmeter, which allowed for simultaneous measurements of tumor blood flow and blood oxygenation. Using this hybrid instrument we continually measured tumor hemodynamic responses to chemo-radiation therapy over the treatment period of 7 weeks. We also explored monitoring dynamic tumor hemodynamic changes during radiation delivery. Blood flow data analysis was improved by simultaneously extracting multiple parameters from one single autocorrelation function curve measured by DCS. Patients were classified into two groups based on clinical outcomes: a complete response (CR) group and an incomplete response (IR) group with remote metastasis and/or local recurrence within one year. Interestingly, we found human papilloma virus (HPV-16) status largely affected tumor homodynamic responses to therapy. Significant differences in tumor blood flow index (BFI) and reduced scattering coefficient (μs’) between the IR and CR groups were observed in HPV-16 negative patients at Week 3. Significant differences in oxygenated hemoglobin concentration ([HbO2]) and blood oxygen saturation (StO2) between the two groups were found in HPV-16 positive patients at Week 1 and Week 3, respectively. Receiver operating characteristic curves were constructed and results indicated high sensitivities and specificities of these hemodynamic parameters for early (within the first three weeks of the treatment) prediction of one-year treatment outcomes. Measurement of tumor hemodynamics may serve as a predictive tool allowing treatment selection based on biologic tumor characteristics. Ultimately, reduction of side effects in patients not benefiting from radiation treatment may be feasible.